Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy.
Ya-Qian XuYan WangChenwei YuanXiaonan ShengRui ShaHuijuan DaiShan ZhangYaohui WangYanping LinLiheng ZhouShuguang XuJie ZhangWenjin YinJinsong LuPublished in: Therapeutic advances in medical oncology (2020)
Our study suggests that EPIC1 may be a promising biomarker for both neoadjuvant chemosensitivity and long-term clinical outcomes in breast cancer, specifically in the HorR-positive premenopausal subgroup. It may also help identify candidate responders and determine treatment strategies.